Prescient Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
James McDonnell
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.2yrs |
| Board average tenure | 9.3yrs |
Recent management updates
Recent updates
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Jul 05
We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth
Mar 12We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate
Nov 14Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth
Aug 01Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why
Nov 22Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Oct 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Jun 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Feb 27We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now
Nov 05We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth
Aug 26Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans
May 08Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?
Jan 11
CEO
James McDonnell
less than a year
Tenure
Mr. James McDonnell is Chief Executive Officer of Prescient Therapeutics Limited from 2025. He is a seasoned leader in the biopharmaceutical industry, bringing many years of global experience in pharmaceut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 10.8yrs | AU$97.96k | 0.027% A$ 10.3k | |
| Chief Executive Officer | less than a year | no data | no data | |
| CFO & Company Secretary | 10.1yrs | AU$158.40k | no data | |
| Director of Clinical Affairs & Operations | 1.2yrs | no data | no data | |
| Chief Medical Officer | 9.9yrs | AU$157.36k | no data |
1.2yrs
Average Tenure
69yo
Average Age
Experienced Management: PTX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 10.8yrs | AU$97.96k | 0.027% A$ 10.3k | |
| Independent Non-Executive Director | 10.3yrs | AU$61.41k | 0.049% A$ 18.6k | |
| Chairman of Clinical Advisory Board | 13.8yrs | no data | no data | |
| Member of Clinical Advisory Board | 13.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 10.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 9.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 9.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 9.2yrs | no data | no data | |
| Non-Executive Director | 4.8yrs | AU$61.41k | no data | |
| Member of Scientific Advisory Board | 4.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.6yrs | no data | no data |
9.3yrs
Average Tenure
Experienced Board: PTX's board of directors are considered experienced (9.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 14:17 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prescient Therapeutics Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paul Hickman | Edison Investment Research |
| Joseph Pantginis | H.C. Wainwright & Co. |